- Deployment of the coronavirus vaccine remains somewhat rugged in the United States, trapped by everything from states with complex receptor levels to follow, to supply limits.
- President-elect Joe Biden made statements on Friday about his plan to significantly improve the launch of the COVID vaccine after next week, when he and Vice President-elect Kamala Harris take office.
- Meanwhile, interim findings associated with Johnson & Johnson’s coronavirus vaccine trial show significant promise, suggesting that another COVID vaccine will soon be authorized in the United States.
News about the coronavirus vaccine continues to rise, with the weekend bringing a host of news, including the Trump administration fooling the nation about the size of the U.S. vaccine reserve to President-elect Biden revealing more details of its national COVID. vaccine strategy. The latter, among other things, will involve encouraging states to abandon complicated levels and make more vaccination sites and federal resources available so that the rate of vaccination can be drastically increased. As for the first, it seems that the Trump administration is either directly lying or badly done (or some combination of the two) when it comes to U.S. vaccine reserves.
Trump administration Secretary of Health and Human Services Alex Azar had announced Tuesday that the administration “would release all (vaccine) supplies by state order, rather than keep the second doses in reserve.” Except, you see, according to what a senior administration official said CNN, what a reservation we had already sold out. At least the news about the vaccine isn’t entirely bad; just look at the new data from the essays published earlier this week in the New England Journal of Medicine in terms of safety, efficacy, and possible side effects of Johnson & Johnson’s new single-dose coronavirus vaccine.
Today’s offer 
Try the best-selling Powecom KN95 masks before they run out. Price:$ 25.99 
Available on Amazon, BGR may receive a commission Available on Amazon BGR may receive a commission
According to the results of the trial, Johnson & Johnson researchers had randomly assigned just over 800 participants to get a high or small dose of the vaccine or a placebo. The results show that after 29 days after vaccination, at least 90% of study participants had developed neutralizing antibodies, a figure that grew to 100% at 57 days after vaccination.
Some of the side effects of Johnson & Johnson’s COVID vaccine, which will soon be released in the U.S., include:
- Fever
- Headache / muscle aches
- Fatigue
- Pain at the injection site
And that’s it, so far. Pain at the vaccine injection site appears to be the most common side effect among participants in the J&J study. Hopefully, this good news helps pave the way for a quick decision on the authorization of Johnson & Johnson’s COVID vaccine in the U.S., where part of the bottleneck has been a self-imposed limitation on vaccine supply. “Self-imposed,” in the sense that the Trump administration’s mistakes included not buying enough of Pfizer’s coronavirus vaccine to make a major move in the U.S. so far, among other things.
Andy is a reporter in Memphis who also contributes to outlets such as Fast Company and The Guardian. When he’s not writing about technology, he can be found crouching down with protection over his growing vinyl collection, in addition to taking care of his whovianism and indulging in various TV shows you probably don’t like.